Depotwettbewerb USA 43 KW
Seite 2 von 3 Neuester Beitrag: 03.12.03 19:50 | ||||
| Eröffnet am: | 20.10.03 05:38 | von: Eskimato | Anzahl Beiträge: | 74 |
| Neuester Beitrag: | 03.12.03 19:50 | von: preisfuchs | Leser gesamt: | 13.458 |
| Forum: | Börse | Leser heute: | 4 | |
| Bewertet mit: |  | |||
| Seite: < 1 | | 3 > | ||||
Gruss E.
Vion Licenses Triapine(R) Rights in China, Taiwan, Hong Kong and Macao
NEW HAVEN, Conn., Oct 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- VION
PHARMACEUTICALS, INC. (Nasdaq: VION) announced today that the Company had
entered into a license agreement with Beijing Pason Pharmaceuticals, Inc.
("Pason") related to the exclusive rights to develop, manufacture and market
Triapine(R) for anticancer and antiviral uses in the mainland of the People's
Republic of China, Taiwan, Hong Kong and Macao (the "Territory"). The agreement
awaits final approval from various government agencies of the People's Republic
of China.
The terms of the agreement include an initial payment of $500,000 upon receipt
of required approvals, $4.75 million in additional milestone payments, and
royalty payments of 11% of any Triapine(R) revenues in the Territory. Pason will
fund the preclinical and clinical development necessary for regulatory approval
of Triapine(R) in the Territory.
According to the Ministry of Public Health of the People's Republic of China
(MPH-PRC) and the Chinese Pharmaceutical Association (CPA), China has 1 million
people infected with human immunodeficiency virus (HIV) (source: MPH- PRC), 20
million chronic hepatitis B (HBV) patents (source: MPH-PRC), and a total of 4.5
million cancer patients (source: CPA). In addition, 2 million new cancer
patients are diagnosed every year (source: CPA). China spends nearly $1 billion
on anti-cancer drugs (source: CPA) and $6 billion on anti-HBV medication
(source: MPH-PRC) each year.
Alan Kessman, Chief Executive Officer of Vion, said, "We are pleased to be in
partnership with Pason to commercialize Triapine(R) in China, Taiwan, Hong Kong
and Macao. The potential markets in these regions for the treatment of cancer
and viral disease are substantial."
Dr. Sen Liu, the Chief Executive Officer of Beijing Pason Pharmaceuticals said,
"We believe that Pason's license of Triapine(R) is among the first such
technology transfers in the pharmaceutical industry in China since its entrance
into the World Trade Organization." He added, "We are glad to collaborate with
Vion to develop Triapine(R) in China. It is our belief that, by licensing
patents and new technology, China's pharmaceutical companies will be able to
develop high quality chemical drugs more effectively. Collaborations with
foreign companies will improve our product pipeline, and in the long run,
benefit patients."
Vion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel
agents for the treatment of cancer. Vion's portfolio of agents includes:
Triapine(R), a potent inhibitor of a key step in DNA synthesis; VNP40101M, a
unique DNA alkylating agent; and TAPET(R), a modified Salmonella vector used to
deliver anticancer agents directly to tumors. For additional information on Vion
and its research and product development programs, visit the company's Internet
web site at www.vionpharm.com.
Beijing Pason Pharmaceuticals, Inc. ("Pason") is a pharmaceutical company
focused on the development of anti-cancer and anti-HBV drugs. Pason's products
include: BP9906, an anti-HBV agent and BP-Inter 014, an anti-cancer agent. Pason
also has a subsidiary that specializes in developing and distributing diagnostic
products for infectious diseases. For more information, visit
www.pason-pharm.com.
This news release contains forward-looking statements. Such statements are
subject to certain risk factors which may cause Vion's plans to differ or
results to vary from those expected, including Vion's ability to secure external
sources of funding to continue its operations, the inability to access capital
and funding on favorable terms, continued operating losses and the inability to
continue operations as a result, its dependence on regulatory approval for its
products, delayed or unfavorable results of drug trials, the possibility that
favorable results of earlier clinical trials are not predictive of safety and
efficacy results in later clinical trials, the need for additional research and
testing, and a variety of other risks set forth from time to time in Vion's
filings with the Securities and Exchange Commission, including but not limited
to the risks discussed in Vion's Annual Report on Form 10-K for the year ended
December 31, 2002. Except in special circumstances in which a duty to update
arises under law when prior disclosure becomes materially misleading in light of
subsequent events, Vion does not intend to update any of these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Greetz f-h
Bei VION kann man die Uhr nach dem Ausbruch stellen...meine ging nach :-(
Mit USXP bin ich nicht zufrieden;hatte da mehr erwartet.Da ich sie auch privat(wie f-h)halte,muss ich mal abwarten,ob der ganze "Newsflow"auch etwas an Substanz enthält.Schliesslich sind auch bei den Pennys 20-30% Verlust übel.
So,schönen Abend noch B.L.
big l. ELNK ist mir nicht entgangen, klasse. Da Longterminvestments auch ans Ziel führen, bin ich wirklich sehr zufrieden, dass Patzi mitspielt. Ich schätze seine Ruhe in SMTS und in seinen anderen Shares. Er hat alle seine Shares noch mal ausführlich vorgestellt letzte Woche, hat mir sehr gefallen.
Gruss E.
Media Advisory - Oncolytics Biotech to Present at Rodman & Renshaw Techvest Healthcare Conference
CALGARY, Oct 20, 2003 (Canada NewsWire via COMTEX) -- Dr. Brad Thompson,
President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will
present a corporate overview of the Company at the Rodman & Renshaw Techvest
Healthcare Conference on Wednesday, October 22nd at 9:00 AM (ET). Oncolytics is
one of 200 invited companies to present at this conference to be held at the
Boston Marriott Long Wharf Hotel October 21-23, 2003.
A live audio webcast of the presentation will be available at:
http://www.wallstreetwebcasting.com/webcast/rrshq/oncy or on the company's
website at www.oncolyticsbiotech.com.
It is recommended that listeners log on 15 minutes in advance of the
presentation to register and download any necessary software. An audio replay
will be available following the presentation on the Rodman and Renshaw website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development
of REOLYSIN(R), its proprietary formulation of the human reovirus, as a
potential cancer therapeutic. Oncolytics' researchers have demonstrated that the
reovirus is able to selectively kill human cancer cells in vitro that are
derived from many types of cancer, including breast, prostate, pancreatic and
brain tumours, and have also demonstrated successful cancer treatment results in
a number of animal models. Phase I clinical trial results have indicated that
there were no toxicology-related issues with the administration of the reovirus,
and that the reovirus demonstrated activity in tumours injected with
REOLYSIN(R).
The webcast time is subject to change. This release and the presentation related
thereto contain forward-looking statements which involve known and unknown
risks, delays, uncertainties and other factors not under the Company's control
and which may cause actual results, performance or achievements of the Company
to be materially different from the results, performance or expectations implied
by these forward-looking statements.
VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION:
http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=56839
CONTACT: For further information: For Canada: Oncolytics Biotech Inc.: Cathy
Ward, 210, 1167 Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel:
(403) 670.7377, Fax: (403) 283.0858, www.oncolyticsbiotech.com; For Canada:
The Equicom Group, Joanna Longo, 20 Toronto Street, Toronto, Ontario, M5C 2B8,
Tel: (416) 815.0700 ext. 233, Fax: (416) 815.0080, jlongo(at)equicomgroup.com;
For United States: The Investor Relations Group, Gino De Jesus or Dian
Griesel, Ph.D., 11 Stone St, 3rd Floor, New York, NY, 10004,
T: (212) 825.3210, F: (212) 825.3229, theproteam(at)aol.com
News release via Canada NewsWire, Toronto 416-863-9350
Copyright (C) 2003 CNW, All rights reserved
Ciao B.L.
Da klemmt watt mächtig!
Handlungsbedarf is angesacht.
Also, Kupplung treten und scharf bremsen!
Die Nummern 2,3,4,5 und 6 müssen raus, um den Totalschaden des gruenen Motors zu vermeiden.
Am WE gehts in die Werkstatt und ein neues 6-Gang- Getriebe kommt rein!
Wird aber erst in den späteren sonntäglichen Abendstunden, da am WE mächtig gewaltig gruene Party angesacht is, wei der gruene Span gestern Geburtstach hatte und der große vielbeschäftigte Gruenspan- Clan wie gesacht am WE aus allen Himmelsrichtungen in die Greenlight- Ranch einrückt (um hoffentlich reichlich und große Geschenke abzuladen) aber dafür den Whisky- Keller (auf Cowboyart) bis zum Umfaller plündert.
FAKTEN:
AGRD SK/VK 0,0089 (5516292) = $49095 " 24 Mio. gingen um "
AESP SK/VK 0,94 ( 13269) = $51277 " 430.000 gingen um "
PCIS SK/VK 4,10 ( 54402) = $54402 " 350.000 gingen um"
BTLY SK/VK 0,039 (1443970) = $56314 " 7,5 Mio. gingen um"
CESY SK/SL 0,005 (8926363) = $44632 " 200 Mio. gingen um"
---- ----- ----- -------- = $255720
---- ----- ----- -------- + $98190 (aus Posting 14)
---- ----- ----- -------- = 353910 Dollar als Endsumme der KW 43 als Cash!
So, ich habe für diese Woche hier fertig.
Bin eigentlich mit der Performance zufrieden und hab auch einen Wert entgegen den Regeln bei unterschrittenen SL zum selbigen ausgebucht.
Alle zum Verkauf erforderlichen Stückzahlen gingen um!
Somit warten nach Kopfrechnerspan 353910 Dollar aufs WE um wieder investiert zu werden.
Neue gruene (vielleicht vernünftigere) Absacker werden dann Sonntag bis 24:00 hier angezeigt.
Bis dahin wünsche ich euch watt!
Gr.Gr.
Optionen
| Boardmail an "Gruenspan" |
Wertpapier: RETEK INC |
Abrechnung mache ich später.Danke B.L.
announced that a Nasdaq Listing Qualifications Panel has granted the Company an exception
to the $1.00 minimum bid price requirement to allow for further developments in the U.S.
Securities and Exchange Commission rule-making process. The exception extends through
December 1, 2003.
Financial Relations Inc: Stocks of Interest and Stocks on the Move on the OTCBB for October 20, 2003 from HotStockChat.com
Virginia Beach, VA, Oct 20, 2003 (M2 PRESSWIRE via COMTEX) --
HotStockChat.com`s morning scans of moving stocks on the OTCBB and Pink Sheets
revealed a moderate list of stocks on the move today. Volume is moderate on the
OTCBB so far today.
Among Stocks of interest today, Centrex, Inc. (OTCBB: CNEX) is up .028 or 34
percent to .11. SmarTire Systems Inc. (OTCBB: SMTR) is up 13 percent so far this
morning. Nexus Telocation Systems Ltd (OTCBB: NXUS) is in the midst of another
big move today. Advanced Optics Electronics Inc. (OTCBB: ADOT) is coming back
nicely after the sell off on Friday. And Synbiotics Corporation (OTCBB: SBIO)
has hit another 52-week high today.
Und eine schöne Feier für Grueni, herzlichen Glückwunsch nachträglich.
Schade, mein fetter SOFO Gewinn ist aufgezehrt, aber die Woche ist noch lang, zwei negative Tage in Folge, Newsflow ist gut für SOFO, nur Gewinnmitnahmen. Morgen gehts wieder hoch mit SOFO denke ich, Korrektur ist ein bisschen zu scharf.
Gruss E.
PRTL sieht wohl die 10 Dollar am Ende des Jahres, ohoh.
Gruss E. und tschüss für heute.
Borland Launches Next Generation Java Development Environment: Borland JBuilder X New Development Environment Reinforces Borland Java(TM) Leadership; Offers Most Significant Product Enhancement in Two Years; Wins Support of Thriving Third Party Ecosy
SCOTTS VALLEY, Calif., Oct 21, 2003 (BUSINESS WIRE) -- Borland Software
Corporation (Nasdaq: BORL) today announced the launch of Borland(R) JBuilder(R)
X, the latest version of the company's industry leading cross-platform
integrated development environment (IDE) for Java(TM). JBuilder X marks the most
significant release of the product in over two years and introduces over 100 new
and enhanced features targeted to increase the productivity of enterprise teams,
corporate developers and code-centric Java developers. The product's new
functionality focuses on usability and productivity; Web application, Web
services and EJB development as well as J2EE(TM) deployment.
Notable new feature additions to JBuilder X are designed to reflect current
trends in the Java market. The IDE offers advanced Web application development
support that includes a standards-based visual designer for the Apache(TM)
Struts framework and first-time comprehensive support for the popular open
source application server JBoss(R).
"JBuilder X exemplifies the next generation Java IDE. We met with thousands of
JBuilder users and surveyed hundreds of enhancement requests to make sure that
we could meet the needs of today's Java developers," commented George Paolini
vice president and general manager of Java solutions at Borland. "Among the top
requests that we have delivered upon is increased customizability. Formerly a
best kept secret at Borland, we have extended our OpenTools API, first published
in 1998. This allows us to continue to support the ecosystem around JBuilder and
offer customers additional functionality from our third-party community."
Importantly, JBuilder X can be extended through the Java Swing-based OpenTools
application programming interface (API). As a result, JBuilder X launches with
over 80 third-party reusable components and plug-ins offering additional
value-add to JBuilder customers. Companies shipping plug-ins with JBuilder X
include Altova, Crystal Decisions, Oracle, salesforce.com, Sun and Sybase.
Next Generation Java(TM) Development Environment
While continuing the trend of simplifying Java development, JBuilder X is
designed to take Java programming to the next level for both the seasoned
professional Java developer and newer Java developers, helping to ensure a rapid
application development approach to Java programming without trade-offs such as
scalability encountered by some of the new RAD-style Java development
environments aimed at less skilled users.
"The creation of J2EE applications continues to challenge IT organizations many
who are still struggling to migrate skilled developers from other technologies,"
commented Thomas Murphy, META Group. "Too often solutions seem to lock companies
into specific J2EE platforms and after the initial code generation and first
release is over, leave developers short without the tools required to design,
develop, and maintain complex applications."
JBuilder X is designed to help developers write better code with the inclusion
of Optimizeit Suite 6.0 for performance profiling and Automatic Quality
Analysis. Enhanced integration with Borland Application Lifecycle Management
(ALM) solutions and with hundreds of third party tools and components helps
ensure that resulting software is aligned with overall business needs.
ALLN läuft heute aber auch nicht schlecht... akt. +20% da freut sich mein Depot!!
Grüße
Pavian
169.759 USXP 0.10 = 16.975,90
2.000 ELNK 8.52 = 17.040,--
Cash: 34.015,90
Zusammen mit dem Cash aus Verkauf von WGFL (19.250,--) damit Gesamtcash: 53.265,90.
Danke und Ciao B.L.
Unsere AVAN haben heute bei den Zahlen ganz schön auf die Mütze gekriegt.Dafür steigt GSS (ich glaube,ich hatte die als einziger hier)unaufhörlich.Langer Atem zahlt sich manchmal aus.
Da sich sonst keiner meldet,hoffe ich auf nicht so schlimme Performance.
Bis morgen B.L.
Aus 40000 Anfangskapital im Moment 353911,54 gemacht.
So viel mal zwischendurch. Seine Shares sind auch nach vielen Wochen ein Traum. Eine von vielen ist CURN, die er in der 25 kw verkauft hat zu 1,25. IVAN hatte er in der gleichen Woche zu 0,96 gekauft. Diese Liste könnte man beliebig fortsetzen, z.B. sein Kauf von BFUN zu 0,42 in der 23 KW. Der geneigte Beobachter weiss, dass BFUN dann 600% in einem Monat gemacht hatte. etc, etc, etc.
Nur dass mir niemand behauptet, kann doch gar nicht sein.
Gruss E.
Muss das sein?
Gruss E.
Lone Star Technologies 3rd-Quarter Loss Widened
Thursday, October 16, 2003 05:59 AM ET Printer-friendly version
DALLAS (Dow Jones)--Lone Star Technologies Inc.'s (LSS, news) third-quarter loss widened to $17.1 million from $10.4 million a year earlier as weak demand for oil country tubular goods used in deep wells continued. However, the company expects fourth quarter performance to improve, citing several postive trends.
On a per share basis, the company posted a loss of 60 cents a share compared with a loss of 37 cents a share a year earlier. This is wider than a Thomson First Call projection of a 50 cents a share loss based on a survey of 9 analysts.
The latest-quarter loss included charges for employee severance, plant consolidations and inventory writedowns of about $2.6 million.
Revenue fell 7.4% during the quarter to $132 million from $142.7 million a year ago.
Lone Star Technologies based its fourth-quarter projection on an expected increase in deeper oil drilling and an expected reduction in steel costs.
Lone Star also said it expected its third-quarter cost cutting efforts to bear fruit in the fourth quarter. The company expects the cost cuts to save about $5 million annually.
The company had said it was planning to cut jobs, delay raw material purchases and modify operating schedules.
First Call projects a fourth-quarter loss of 23 cents a share based on a survey of nine analysts.
Lone Star Technologies makes oilfield casing, tubing and pipe products.
Lone Star Technologies Inc. (LSS, news) - Dallas
3rd Quar Sept. 30:
2003 2002
Revenue $132,000,000 $142,700,000
Net income a (17,100,000) (10,400,000)
Avg shrs (diluted) 28,500,000 28,500,000
Shr earns
Net income a (.60) (.37)
Figures in parentheses are losses.
a. Includes an income tax expense of $100,000.
Company Web site: http://www.lonestartech.com
-Jerry Abejo; Dow Jones Newswires; 201-938-5400
Dow Jones Newswires
10-16-03 0559ET
Copyright 2003 Dow Jones & Company, Inc. All Rights Reserved.
Moin, Fans!
Gesunde Marktkonsolidierung setzt nach letzten Earnings ein.
Da hab ich ja mit meinen Verkäufen in dieser KW sogar richtig gut gelegen.
Ich denke, in dieser Woche wird net mehr viel im Aktiensegment insgesamt zu holen sein.
AMAZON, DUPONT, AMGEN, GP MORGAN, u.s.w. mit eher schlechteren Aussichten bremsen zum Glück datt Entstehen einer neuen größeren Blase.
Asien fügt sich nun auch nahtlos an.
Zumindest kurzfristig wurde mehr auf Unternehmensaussagen und weniger auf doch mehr und mehr positivere Konjunkturdaten geachtet.
An Gewinnmitnahmen is ja bekanntlich och noch keiner gestorben!
Ok, es gibt tagtäglich schöne Chancen und auch viele längerfristige Sachen (Eski zählt selbige immer so schön auf)(könnte noch ne ganze Latte dranhängen), aber wie ich an anderer Stelle schon sagte:
Lieber jetzt die schnelle Aktien- Knete mitnehmen, um bald bzw. je nach Lage, wieder die richtig guten Langfristler (Outperformer) billiger als zur Stunde einsammeln.
Die wiederum zu finden is net so schwer, aber mein Durchhaltevermögen lässt mich immer im Stich, datt is mein Problem und wird es sicher auch bleiben.
PS: Nächsten Dienstag tagt die Fed!
Greenspan bringt die Aktienmärkte dann wieder auf Kurs!
Zur Zeit gilt bei mich jedoch - A. i. P. !!
A l l e s i n P u t t e r !
560461 KK 1,16
Ich wünsche euch einen erfolgreichen Tag!
Gr.Gr.
Optionen
| Boardmail an "Gruenspan" |
Wertpapier: RETEK INC |
Wenn Eski nich so verliebt in seine Outperformer wäre, hätte er och ne schöne Woche.
Aber, wie sagte er doch: "Die Woche is noch lang!"
Hmmmm ......
Ihr kriegt datt sicher hin, oder?
Gr.Gr.
Optionen
| Boardmail an "Gruenspan" |
Wertpapier: RETEK INC |
Das erklär mir mal.
Ja, hätte Gewinne mitnehmen können, sollen? und hab es nicht gemacht. Denke aber, noch mit nem Wochenplus rauszugehen, das ist ok.
Pavian hat zwei Megavolltreffer mit SBIO und ALLN, wird wieder seine Woche werden, klasse.
Gruss E.
Gruss E.
Kopfrechnerspan hat die 100 nich abgezogen *gg*
Macht aber nüscht, weil, die kommen nächste Woche eh drauf!
;-)
Optionen
| Boardmail an "Gruenspan" |
Wertpapier: RETEK INC |